EBEugenia E. Bashmakova

Eugenia E. Bashmakova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eugenia E. Bashmakova has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Bioluminescent aptamer-based microassay for detection of melanoma inhibitory activity protein (MIA)

    by Eugenia E. Bashmakova, Alexander N. Kudryavtsev, Alexey E. Tupikin, Marsel R. Kabilov, Aleksey E. Sokolov, Ludmila A. Frank

    Melanoma inhibitory activity protein (MIA) does obviously offer the potential to reveal clinical manifestations of melanoma. Despite a pressing need for effective diagnosis of this highly fatal disease, there are no clinically approved MIA detection ELISA kits available. A recommended MIA threshold has not yet been defined, mostly by reason of variability in immunoglobulins' affinity and stability, the difference in sample preparation and assay conditions. Here we present a pair of high-affinity DNA aptamers developed as an alternative recognition and binding element for MIA detection. Their stability and reproducible synthesis are expected to ensure this analysis under standard conditions. The devised aptamer-based solid-phase microassay of model standard and control human sera involves luciferase NLuc as a highly sensitive reporter. Bioluminescence dependence on MIA concentration ranges in a linear manner from 2.5 to 250 ng mL−1, providing a MIA detection limit of 1.67 ± 0.57 ng mL−1.


  • Open Access

    On the diagnostic and prognostic significance of the oncomarker survivin (BIRC5) in bladder cancer

    by Никита Панамарев, Евгения Башмакова, Александр Кудрявцев, Денис Черняев, Андрей Мазаев, Евгений Слепов, Руслан Зуков, Людмила Франк

    Цель исследования. Оценить содержание сурвивина в моче как диагностического маркера рака мочевого пузыря (РМП); изучить прогностическое значение полиморфизма -31G>C (rs9904341) в промоторной области гена BIRC5 в отношении агрессивности течения РМП среди населения Красноярского края. Материалы и методы. Иммуноанализом определен сурвивин в 43 образцах мочи пациентов: с РМП — 27, другим вариантом злокачественного новообразования — 4, воспалительными заболеваниями мочеполовой системы и доброкачественной гиперплазией — 8, здоровых — 4. Разработанным авторами способом на основе биолюминесцентного анализа генотипированы образцы ДНК 285 пациентов с РМП и 183 здоровых доноров. Количественные данные сравнивали U-тестом Манна-Уитни, критерием χ2 Пирсона — частоты генотипов среди случаев РМП и контролей. Ассоциацию между полиморфизмом и РМП оценивали по отношению шансов с 95 % доверительным интервалом, p < 0,05 считали значимым. Результаты. Установлено, что определение сурвивина в моче позволяет разделять пациентов с РМП и здоровых с чувствительностью 66,7 % и специфичностью 100 %. Повышенное содержание сурвивина обнаружено в образцах пациентов с воспалительными заболеваниями и доброкачественными гиперплазиями мочевыводящих путей. Показано, что полиморфизм -31G>C (rs9904341) для пациентов Красноярского края при оценке риска возникновения РМП и развития рецидива заболевания не является значимым. Носительство аллеля GG является возможным предиктором агрессивного течения заболевания с быстрым прорастанием в мышечную стенку мочевого пузыря (48,7 % vs 35,7 %, p = 0,02). Заключение. Сурвивин является хорошим преддиагностическим маркером для выявления пациентов с заболеваниями мочевых путей: его повышенный уровень в моче может указывать на развитие злокачественных (в т. ч. РМП) и доброкачественных гиперплазий, а также воспалительных заболеваний уротелия. Разработка отечественной «аларм» тест-системы по определению сурвивина в моче для быстрой и неинвазивной диагностики перспективна. Полиморфизм -31G>C (rs9904341) можно рассматривать как предиктор агрессивного течения РМП.


  • Open Access

    Relationship of -31G/C (rs9904341) polymorphism in the survivin gene BIRC5 and the risk of bladder cancer

    by E. E. Bashmakova, N. S. Panamarev, A. N. Kudryavtsev, D. V. Chernyaev, E. V. Slepov, R. A. Zukov, L. A. Frank

    Purpose: To study the relationship between the -31G/C (rs9904341) polymorphism in the promoter region of the survivin protein gene and the predisposition to bladder cancer (BC) in patients of the Krasnoyarsk region. Material and methods. The allelic composition of the studied gene was determined in a group of 158 BC patients, consisting of 30 women and 128 men (mean age 65.6 ± 10.7, median: 66.5; C25–C75: 59–72). The control group included 117 healthy donors and consisted of 27 women and 90 men with an average age of 60.2 ± 5.1 (median: 60; C25–C75: 57–63.25). The allelic composition was determined using the bioluminescent method. A sample with the GC genotype confirmed by sanger sequencing (center for collective use “genomika”, Novosibirsk, Russia) was used as a control. The Mann–Whitney U test was used to compare quantitative data. the studied sample was in Hardy–Weinberg equilibrium (p>0.5). The pearson χ2 test was used to compare the frequencies of gene variants among BC cases and control samples. The association between variants rs9904341 and BC was assessed in terms of odds ratio (OR) with a 95 % confidence interval (CI); p valuesResults. The allelic composition was determined for the genes of patients and control group participants: GG – 62 (39.2%) vs 43 (36.8%); GC – 82 (51.9%) vs 54 (46.2%); CC – 14 (8.9%) vs 20 (17.15%). The relationship between the presence of the C allele and BC was assessed using the recessive inheritance model, combining all carriers – heterozygotes and homozygotes. The frequency of occurrence of genotypes for patients and the control group was established: GG + GC – 144 (91.1%) vs 97 (82.9%); CC – 14 (8.9%) vs 20 (17.1%). Thus, carriers of the CС genotype were significantly less in patients: OR (95% CI) 0.47 (0.23–0.98), p=0.04. The relationship with tumor invasion was not significant (p=0.08). Conclusion. Based on the results of detecting the rs9904341 (G/C) polymorphism among BC patients of the Krasnoyarsk region, a protective effect of the carriage of the CC genotype was found. In order to study the allelic composition with the threat of recurrence of the disease, additional research is needed.


  • Open Access

    Coelenterazine-Dependent Luciferases as a Powerful Analytical Tool for Research and Biomedical Applications

    by Vasilisa V. Krasitskaya, Eugenia E. Bashmakova, Ludmila A. Frank

    The functioning of bioluminescent systems in most of the known marine organisms is based on the oxidation reaction of the same substrate—coelenterazine (CTZ), catalyzed by luciferase. Despite the diversity in structures and the functioning mechanisms, these enzymes can be united into a common group called CTZ-dependent luciferases. Among these, there are two sharply different types of the system organization—Ca2+-regulated photoproteins and luciferases themselves that function in accordance with the classical enzyme–substrate kinetics. Along with deep and comprehensive fundamental research on these systems, approaches and methods of their practical use as highly sensitive reporters in analytics have been developed. The research aiming at the creation of artificial luciferases and synthetic CTZ analogues with new unique properties has led to the development of new experimental analytical methods based on them. The commercial availability of many ready-to-use assay systems based on CTZ-dependent luciferases is also important when choosing them by first-time-users. The development of analytical methods based on these bioluminescent systems is currently booming. The bioluminescent systems under consideration were successfully applied in various biological research areas, which confirms them to be a powerful analytical tool. In this review, we consider the main directions, results, and achievements in research involving these luciferases.


  • Bioluminescent aptamer-based solid-phase microassay to detect lung tumor cells in plasma

    by Eugenia E. Bashmakova, Vasilisa V. Krasitskaya, Galina S. Zamay, Tatiana N. Zamay, Ludmila A. Frank


  • Development and characterization of novel 2′-F-RNA aptamers specific to human total and glycated hemoglobins

    by Anna Davydova, Mariya Vorobyeva, Eugenia Bashmakova, Pavel Vorobjev, Olga Krasheninina, Alexey Tupikin, Marsel Kabilov, Vasilisa Krasitskaya, Ludmila Frank, Alya Venyaminova


  • Bioluminescent SNP genotyping technique: Development and application for detection of melanocortin 1 receptor gene polymorphisms

    by Eugenia E. Bashmakova, Vasilisa V. Krasitskaya, Alexander A. Bondar, Ekaterina N. Eremina, Eugene V. Slepov, Ruslan A. Zukov, Ludmila A. Frank


  • Genetically Modified Coelenterazine-Dependent Luciferases as Reporters for In Vitro Assay

    by Alexander N. Kudryavtsev, Institute of Biophysics SB RAS Federal Research Center “Krasnoyarsk Science Center SB RAS”, Vasilisa V. Krasitskaya, Eugenia E. Bashmakova, Ludmila A. Frank

  • Mutants of Ca2+-regulated Photoprotein Obelin for Site-specific Conjugation

    by Vasilisa V. Krasitskaya, Ludmila P. Burakova, Anastasia A. Komarova, Eugenia E. Bashmakova, Ludmila A. Frank


  • The genetic aspects of occupational hearing impairment

    by V. V. Krasitskaya, E. E. Bashmakova, K. G. Dobretsov, N. V. Orlova, L. A. Frank, В. В. Красицкая, К. Г. Добрецов, Сурдолог Орлова

    Medical article медицинская статья